South San Francisco, CA, United States of America

Klara Totpal

This inventor holds 1 USPTO granted patent. Top assignee: Genentech, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Klara Totpal. Retrieved from https://idiyas.com/inventor/klara-totpal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Klara Totpal: Innovator in Antibody Drug Conjugates

Introduction

Klara Totpal is a prominent inventor based in South San Francisco, CA. She has made significant contributions to the field of biotechnology, particularly in the development of innovative treatments using bispecific antibodies. Her work is instrumental in advancing therapeutic options for patients.

Latest Patents

Klara holds a patent titled "Dosing for Treatment with Anti-CD20/Anti-CD3 Bispecific Antibodies and Anti-CD79B Antibody Drug Conjugates." This patent reflects her expertise in creating targeted therapies that enhance the efficacy of cancer treatments.

Career Highlights

Klara is currently employed at Genentech, Inc., a leading biotechnology company known for its focus on innovative medicines. Her role at Genentech allows her to collaborate with some of the brightest minds in the industry, contributing to groundbreaking research and development.

Collaborations

Throughout her career, Klara has worked alongside talented colleagues, including Brendan Christian Bender and Stephen James Simko. These collaborations have fostered an environment of innovation and creativity, leading to advancements in therapeutic strategies.

Conclusion

Klara Totpal's contributions to the field of biotechnology and her innovative patent work exemplify her commitment to improving patient outcomes. Her career at Genentech highlights her role as a key player in the development of cutting-edge therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…